Spectral AI (MDAIW) stock price is $0.51, unchanged on the day, as of Oct 29, 2026. It has a market cap of $50.53Mn, and is classified in the Diagnostic Equipment industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap50.53 Mn
P/E-4.99
FCF (Yr)-9.92 Mn
ROA (Yr)-45.20
EV to EBIT0.09
Net Income (Yr)-7.57 Mn
Enterprise Value-1.07 Mn
Add ratio to table…
About
Spectral AI, Inc. is an AI company focused on predictive medical diagnostics. The company’s core product is the DeepView System which combines multispectral imaging with proprietary AI algorithms to assess wound healing potential. The system provides a binary prediction of whether a wound will heal or not heal within a specified time frame. Its primary focus is on burn indications and it has obtained UKCA marking for that use.
Revenue is expected from two streams once…
Spectral AI, Inc. is an AI company focused on predictive medical diagnostics. The company’s core product is the DeepView System which combines multispectral imaging with proprietary AI algorithms to assess wound healing potential. The system provides a binary prediction of whether a wound will heal or not heal within a specified time frame. Its primary focus is on burn indications and it has obtained UKCA marking for that use.
Revenue is expected from two streams once regulatory clearances are obtained: a software as a service component that charges a licensing fee for maintenance image hosting and algorithm updates and a hardware component that involves the sale of the imaging device. Until then the company relies principally on non dilutive government contracts for funding.
The company holds a differentiated position in the wound care diagnostics market as it claims to be the only AI enabled imaging technology that delivers an immediate binary wound healing assessment. Its competitive advantages include a proprietary database of over 340 billion pixels of image data a suite of patents covering multispectral optics and AI algorithms and strong backing from U. S. government agencies such as BARDA and DHA. No direct competitor offers a comparable point of care prediction that replaces subjective clinician judgment.
The company serves hospitals burn centers trauma centers and emergency rooms primarily in the United States and the United Kingdom. Its customers also include government agencies that fund development such as BARDA the Defense Health Agency and the Medical Technology Enterprise Consortium. While specific institution names are not disclosed the target settings are acute inpatient facilities and outpatient clinics that treat burn wounds.
Sectors:Healthcare·TechnologySector rationaleThe company's core business is predictive medical diagnostics, specifically the DeepView System used in hospitals and burn centers to assess wound healing. While it uses AI and a SaaS model, the primary product is a medical device and diagnostic tool sold to healthcare providers, placing it in Healthcare. A secondary sector of Technology is justified because the company explicitly identifies as an AI company and generates revenue through a software-as-a-service (SaaS) licensing model for algorithm updates and image hosting.Industries:Diagnostic EquipmentDiagnostic EquipmentPrimarySpectral AI develops the DeepView System, which is a clinical diagnostic platform combining multispectral imaging and AI algorithms to predict wound healing. The company sells both the imaging device (hardware) and the associated diagnostic software to hospitals and burn centers.Healthcare ITHealthcare ITSecondaryThe company generates revenue through a software-as-a-service (SaaS) model that provides image hosting and algorithm updates specifically for medical wound diagnostics, embedding clinical workflows and medical data standards.Classified using BQ-MICSCIK: 0001833498